CN111683949A - 一种1H-咪唑并[4,5-b]吡啶-2(3H)-酮类化合物的晶型及其制备方法 - Google Patents

一种1H-咪唑并[4,5-b]吡啶-2(3H)-酮类化合物的晶型及其制备方法 Download PDF

Info

Publication number
CN111683949A
CN111683949A CN201980010305.1A CN201980010305A CN111683949A CN 111683949 A CN111683949 A CN 111683949A CN 201980010305 A CN201980010305 A CN 201980010305A CN 111683949 A CN111683949 A CN 111683949A
Authority
CN
China
Prior art keywords
compound
degrees
solvent
water
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980010305.1A
Other languages
English (en)
Other versions
CN111683949B (zh
Inventor
雷茂义
徐雨
罗云富
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Shijiazhuang Sagacity New Drug Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Sagacity New Drug Development Co Ltd filed Critical Shijiazhuang Sagacity New Drug Development Co Ltd
Publication of CN111683949A publication Critical patent/CN111683949A/zh
Application granted granted Critical
Publication of CN111683949B publication Critical patent/CN111683949B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种1H‑咪唑并[4,5‑b]吡啶‑2(3H)‑酮类化合物(I)晶型及其制备方法和在制备治疗与PDE4受体相关疾病药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201980010305.1A 2018-01-29 2019-01-29 一种1H-咪唑并[4,5-b]吡啶-2(3H)-酮类化合物的晶型及其制备方法 Active CN111683949B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018100857041 2018-01-29
CN201810085704 2018-01-29
PCT/CN2019/073701 WO2019144970A1 (zh) 2018-01-29 2019-01-29 一种1H-咪唑并[4,5-b]吡啶-2(3H)-酮类化合物的晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN111683949A true CN111683949A (zh) 2020-09-18
CN111683949B CN111683949B (zh) 2023-03-21

Family

ID=67395806

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980010305.1A Active CN111683949B (zh) 2018-01-29 2019-01-29 一种1H-咪唑并[4,5-b]吡啶-2(3H)-酮类化合物的晶型及其制备方法

Country Status (7)

Country Link
US (1) US11325907B2 (zh)
EP (1) EP3747884B1 (zh)
JP (1) JP7237973B2 (zh)
CN (1) CN111683949B (zh)
AU (1) AU2019211931B2 (zh)
CA (1) CA3089414A1 (zh)
WO (1) WO2019144970A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867273A (zh) * 2020-09-29 2023-03-28 广州白云山医药集团股份有限公司白云山制药总厂 吡啶并吡唑类化合物的晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018036470A1 (zh) * 2016-08-22 2018-03-01 南京明德新药研发股份有限公司 作为pde4抑制剂的并环类化合物
WO2018036469A1 (zh) * 2016-08-22 2018-03-01 南京明德新药研发股份有限公司 Pde4抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
UY33463A (es) * 2010-06-24 2012-01-31 Takeda Pharmaceutical Compuestos heterocíclicos fusionados
EP2663549B1 (en) * 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
ES2806135T3 (es) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd Nuevos inhibidores de bromodominios bicíclicos
EP3142663A1 (en) * 2014-05-16 2017-03-22 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018036470A1 (zh) * 2016-08-22 2018-03-01 南京明德新药研发股份有限公司 作为pde4抑制剂的并环类化合物
WO2018036469A1 (zh) * 2016-08-22 2018-03-01 南京明德新药研发股份有限公司 Pde4抑制剂
CN109563051A (zh) * 2016-08-22 2019-04-02 南京明德新药研发股份有限公司 作为pde4抑制剂的并环类化合物
CN109661395A (zh) * 2016-08-22 2019-04-19 石家庄智康弘仁新药开发有限公司 Pde4抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867273A (zh) * 2020-09-29 2023-03-28 广州白云山医药集团股份有限公司白云山制药总厂 吡啶并吡唑类化合物的晶型及其制备方法

Also Published As

Publication number Publication date
EP3747884A4 (en) 2021-09-01
AU2019211931B2 (en) 2023-08-10
CN111683949B (zh) 2023-03-21
EP3747884B1 (en) 2022-11-02
RU2020127989A (ru) 2022-02-28
AU2019211931A1 (en) 2020-08-20
CA3089414A1 (en) 2019-08-01
WO2019144970A1 (zh) 2019-08-01
JP7237973B2 (ja) 2023-03-13
JP2021512076A (ja) 2021-05-13
US20210198253A1 (en) 2021-07-01
EP3747884A1 (en) 2020-12-09
US11325907B2 (en) 2022-05-10

Similar Documents

Publication Publication Date Title
JP2021519282A (ja) ＨＩＦ−２−αの阻害薬による消化器系の炎症軽減方法
CN110128382B (zh) 一种水黄皮籽素的制备方法和应用
CN111683949B (zh) 一种1H-咪唑并[4,5-b]吡啶-2(3H)-酮类化合物的晶型及其制备方法
CN114430736A (zh) 含有n杂五元环的衣壳蛋白装配抑制剂的晶型及其应用
CN105461720A (zh) 吗啉类酪氨酸激酶抑制剂
WO2021058001A1 (zh) N杂五元环化合物的晶型及其应用
EP3896063B1 (en) Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1)
CN111592479B (zh) 一种芦荟大黄素氮杂环衍生物及其制备方法和用途
CN105732595A (zh) 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途
CN105218539B (zh) 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN111527073A (zh) 一种4-(萘-1-基)-4h-1,2,4-三唑类类化合物的晶型、盐型及其制备方法
US20190307738A1 (en) Novel dizocilpine derivatives as peripheral nmda receptor antagonists
RU2784538C2 (ru) Кристаллическая форма соединения 1h-имидазо[4,5-b]пиридин-2(3h)-она и способ ее получения
CN114072382B (zh) 一种苯并咪唑-2-酮类化合物的晶型、溶剂化物、溶剂化物的晶型及它们的制备方法
CN114230582A (zh) 新型一叶萩碱二聚体及其制备方法和应用
US11584750B2 (en) Crystalline forms of (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase
CN107260752B (zh) 一种协同抗胰腺癌的药物组合物
CN105111206B (zh) 一种环丙烷甲酰胺衍生物e晶型及其制备方法
WO2023169119A1 (zh) 化合物的固体形式及其制备方法和用途
RU2818103C2 (ru) Соль ингибитора syk и ее кристаллическая форма
CN109232555B (zh) 一种抗hbv的含氧杂环化合物
WO2023006057A1 (zh) 氨基吡唑并嘧啶化合物的晶体
CN117624293A (zh) 一种ddr1亲和肽及其应用
CN106661064A (zh) 一种抗癌化合物的新晶型及其制备方法和用途
CN116023395A (zh) 三环类激酶抑制剂的晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036985

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210719

Address after: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 050000 16th floor, innovation building, 315 Changjiang Avenue, hi tech Zone, Shijiazhuang, Hebei Province

Applicant before: Shijiazhuang Zhikang Hongren New Drug Development Co.,Ltd.

GR01 Patent grant
GR01 Patent grant